Literature DB >> 3458694

In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.

K V Rolston, M E Alvarez, K C Hsu, G P Bodey.   

Abstract

The activity of three new antimicrobial agents [cefpirome (HR 810), BMY 28142, WIN 49375], and imipenem was compared to that of four currently available agents, ceftazidime, aztreonam, timentin and piperacillin, against 253 bacterial isolates from cancer patients. The activity of all four agents not yet in clinical use at our institution was significantly greater than that of the four antibiotics already in use.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3458694     DOI： 10.1093/jac/17.4.453

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

2.  Activity of newer antimicrobial agents against Aeromonas hydrophila.

Authors:  K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

Review 3.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

4.  Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.

Authors:  L O Gentry; G Rodriguez-Gomez
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 5.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.